The 10x Genomics Xenium platform makes this possible with high-resolution, single-cell spatial transcriptomics, uniting histology and deep molecular profiling. In this webinar, Cure51 and Explicyte join forces to show how Xenium is driving the ROSALIND Study, the world’s largest effort to profile rare long-term survivors of aggressive cancers.
Cure51 has established a worldwide collaboration network to enable the identification and collection of these exceptional cases, with the goal of uncovering the biological mechanisms that underlie survival against the odds. Explicyte, one of the first CROs in Europe to adopt the Xenium platform, leverages its spatial profiling expertise to map tumor–immune interactions at single-cell resolution.
Explicyte will also present an in vitro proof-of-concept using Xenium, demonstrating how the STAMP workflow (Pitino et al., Cell 2025) enables simultaneous extraction of cell phenotyping and gene expression data from PBMCs exposed to cancer immunotherapy, thereby capturing subtle shifts within rare cell populations.
Founder & CEO
Explicyte
Co-Founder & Senior Scientific Advisor,
Cure51
Scientific Technical Advisor
10x Genomics